All News
ACR 2022 Guideline on Glucocorticoid-Induced Osteoporosis
The ACR has published its updated recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP) for patients receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily.
Read Article
PMR and Telemedicine: do we really need an office visit?
When we are considering a diagnosis of PMR, it is key to evaluate the patient accurately and efficiently. Can we use a synchronous audiovisual visit or a rheumatology eConsult to evaluate the patient's symptoms quickly? Does it allow us to make an accurate diagnosis? I would argue that for most of these cases we indeed can.
Read Article
Subcutaneous Remsima, an infliximab biosimilar, has been FDA. Celltrion has rebranded this as Zymfentra, for maintenance therapy in adults with moderately to severely active Ulcerative colitis and Crohn's disease following (after giving IV infliximab) https://t.co/gvcssRuB92 https://t.co/dPYVi10KIA
Dr. John Cush RheumNow ( View Tweet)
Korean Insurance matched (1:10) claims cohort study (2010-2017) found bronchiectasis in 5.3% of 4845 systemic sclerosis pts vs 1.9% of non-SSc controls (24,225). SSc pts have a signif higher risk of bronchiectasis (adj HR 2.63), thus a minor feature of SSc https://t.co/7oOBkpw2DM https://t.co/683I0mMmQI
Dr. John Cush RheumNow ( View Tweet)
What Goes Wrong with the Immune System in #PMR?
Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease. Imaging studies have revealed that PMR should not be viewed as a mysterious source of pain and stiffness.
https://t.co/bQDcpM1ymQ https://t.co/B5anJolukY
Dr. John Cush RheumNow ( View Tweet)
#PMR TNR Pearls
Lessons learned from this months Tuesday Nite Rheumatology (TNR) sessions.
https://t.co/HiYcHL52hO https://t.co/z0xuYODLXV
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Bimekizumab for Plaque Psoriasis
UCB announced today that the FDA has approved bimekizumab-bkzx (Bimzelx)) for the treatment of moderate to severe plaque psoriasis in adults who needing systemic therapy or phototherapy.
https://t.co/BqeSAAxtQb https://t.co/LFjzkmAC5w
Dr. John Cush RheumNow ( View Tweet)
Using Methotrexate in #PMR
Where in other inflammatory rheumatic disorders, such as RA and PsA, early initiation of MTX is common practice, this is not the case in PMR. Treatment of PMR is still largely based on GC.
https://t.co/fW9BL3YWS5 https://t.co/bQwozOPUvJ
Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Lupus Management Recommendations
EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations.
https://t.co/LainTFQBDg https://t.co/4b4h1fy6M3
Dr. John Cush RheumNow ( View Tweet)
JAKne? Systematic review &meta-analysis (25 studies, 10 839 pts), JAK inhibitor use was associated with an elevated odds of acne (OR 3-5 for UPA, TOFA, BARI, Deucra; but higher for abrocitinib (OR 13.5). Seen in Derm pts but hardly at all in Rheum pts https://t.co/En8HCqwqjO https://t.co/ak216wmlBA
Dr. John Cush RheumNow ( View Tweet)
Genetic links for Raynauds Phen (RP): Large GWAS study of 5147 RP cases in the UK Biobank cohort shows 2 robust and strong (p < 4.8 × 10−13) novel loci A) ADRA2A (rs7090046, OR per allele: 1.26) & B) IRX1 (rs12653958, OR: 1.17) as candidate causal genes https://t.co/W6F736uskO https://t.co/u1IZnIy7wg
Dr. John Cush RheumNow ( View Tweet)
Hong Kong study of 12233 RA pts followed 8.7 yrs, and 7% developed MACE. Daily Pred ≥5 mg signif increased the MACE risk (HR ~ 2), dose-dependent fashion; YET Pred <5 mg/d was not associated with MACE risk (vs No GC) https://t.co/26peaYp4kQ https://t.co/ooax9iTZYo
Dr. John Cush RheumNow ( View Tweet)
12.3 million Americans over 50 have osteoporosis; 47 million have osteopenia. W/ OP Fx the risk of repeat Fx is highest in 1st 6 mos, yet 8% of Medicare pts w/ Fx have a diagnostic bone density scan (less in African Americans 5%) https://t.co/xBHr7WffYf https://t.co/S27Vs8yyjY https://t.co/eWcOB8fjWH
Links:
Dr. John Cush RheumNow ( View Tweet)
Sleep problems in SpA & PsA? Study of 201 pts shows 43% of axSpA and 47% of PsA pts reported sleep problems. In both poor sleep assoc w/ dz activity. In axSpa it signif assoc w/ Dz activity (OR 8.45),biologic use (OR .24), & CRP levels (OR .16) https://t.co/7juI2Dghjh https://t.co/SxCaJgTmeQ
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaque Psoriasis https://t.co/Eo4LMaTHxn https://t.co/abzlThasEN
Dr. John Cush RheumNow ( View Tweet)
#PMR with Cancer
Dr. Sebastian Sattui (Pittsburgh, PA) Can PMR be a paraneoplastic presentation?
https://t.co/GsQ5FoDGPK https://t.co/ybHMmi72TG
Dr. John Cush RheumNow ( View Tweet)
Innovative, full-read, state-of-the-art article on IMAGING in INFLAMMATORY ARTHRITIS & its future role in precision medicine. "Imaging is poised to become an invaluable tool in precision medicine..". HR-pQCT, 3T or 7T MRI, FAPI PET–CT, CEUS, FOI, etc https://t.co/fGQVEOkea9 https://t.co/XyvtZj85Hk
Dr. John Cush RheumNow ( View Tweet)
Check out my other podcast - the Miracle Larry Podcast. Miracle Larry gave the keynote lecture at RNL2023. A podcast focused on his amazing story. Follow us @Miracle_LarryK. We’d appreciate the support!
https://t.co/6zi2D7hdGJ
Links:
Dr. John Cush RheumNow ( View Tweet)
What Goes Wrong with the Immune System in #PMR?
https://t.co/3DDFXBOfaL https://t.co/WNiWpokP4q
Dr. John Cush RheumNow ( View Tweet)
Using Methotrexate in #PMR
Where in other inflammatory rheumatic disorders, such as RA and PsA, early initiation of MTX is common practice, this is not the case in PMR. Treatment of PMR is still largely based on GC.
https://t.co/pQtmYvF2NS https://t.co/wJTpFPqmlw
Dr. John Cush RheumNow ( View Tweet)